Sign In

David Ku, MD

VP Corporate Development @ Jasper Therapeutics

Professional Background

Dr. David Ku is a renowned medical professional currently serving as the Vice President of Corporate Development, Portfolio Strategy, and Management at Jasper Therapeutics, an innovative biotechnology company at the forefront of hematopoietic stem cell therapies. With a strategic mindset and extensive experience in the biopharmaceutical sector, Dr. Ku's contributions to the industry, particularly through his leadership role at Jasper, are noteworthy. At Jasper Therapeutics, he leads corporate development initiatives and is also the program lead for briquilimab, a c-Kit targeting antibody. This role places him at the intersection of scientific innovation and strategic business development, showcasing his ability to navigate both the medical and corporate landscapes effectively.

Prior to his pivotal role at Jasper, Dr. Ku was the Director of Strategic Planning at Gilead Sciences, a global leader in biopharmaceuticals. His tenure involved overseeing crucial planning strategies that aligned Gilead's ambitious research and development goals with the broader objectives of the healthcare market. Notably, he served as Engagement Manager at McKinsey & Company's Pharmaceutical and Medical Products Practice, where he delivered impactful consulting services to biopharma companies, focusing on R&D strategies, portfolio management, and mergers and acquisitions.

Education and Achievements

Dr. Ku's academic journey reflects a strong foundation in both medicine and technology, equipping him with a unique set of skills that enhance his contributions to the biotechnology industry. He earned his Doctor of Medicine (MD) degree with distinction from the Icahn School of Medicine at Mount Sinai, a prestigious institution known for its focus on research and innovation in medical education. His academic excellence set the stage for his impressive career in biotechnology and pharmaceuticals.

In addition to his medical degree, Dr. Ku holds a Bachelor of Science (S.B.) in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology (MIT). This combination of technical knowledge and medical training enables him to implement cutting-edge technologies and strategies in the development of life-saving therapies. His experiences during his time at MIT, particularly with the High-Throughput Neurotechnology Group, cultivated his skills in applying engineering principles to biological research, fostering a holistic approach to the challenges faced within the biopharmaceutical landscape.

Notable Achievements

Dr. Ku's career is marked by several significant achievements that highlight his expertise in strategic planning and corporate development. At Jasper Therapeutics, he has influenced the company's strategic direction through innovative approaches in portfolio management. His leadership in the briquilimab program has been essential in advancing therapy options for patients with hematopoietic disorders, demonstrating his commitment to translating scientific research into viable treatment solutions.

Before joining Jasper, Dr. Ku played instrumental roles at Gilead Sciences and McKinsey & Company, where he was pivotal in shaping corporate strategies that resulted in successful product development and market positioning. His experience in strategic planning at Gilead is particularly notable, as he helped guide the organization's initiatives in expanding its global reach and impact on human health.

At McKinsey, Dr. Ku's engagement with high-profile biopharma clients allowed him to refine his skills in managing complex projects that integrate research, market analytics, and financial viability. This experience has provided him with insight into the multifaceted challenges organizations face in an ever-evolving healthcare landscape.

Dr. Ku's proficiency in aligning medical advancements with corporate strategies illustrates his exceptional ability to bridge the gap between science, technology, and business, which is increasingly necessary in today's healthcare environment.

Highlights

Feb 17 · linkedin

It's been incredibly energizing to be back at the Transplantation & Cellular Therapy Meetings of the ASTCT and Center for International Blood & Marrow Transplant Research (CIBMTR)!!

This year has been especially momentous for Jasper Therapeutics with six presentations at the conference highlighting the advancement of our anti-c-Kit antibody briquilimab (JSP191), including two plenary talks to kick off the morning by our founder Dr. Judith Shizuru at Stanford University School of Medicine and our collaborator Dr. John Tisdale at The National Institutes of Health.

For those interested, here are the presentations at this year's meeting #Tandem23:

Plenary S-P3: Conditioning with a Naked Antibody: The Target Matters

Plenary S-P3: Improving the Landscape for Curative Therapies in Sickle Cell Disease with Novel Conditioning Methods

Oral Presentation, Abstract 59: Subanalysis from Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myleoid Leukemia in Complete Remission Undergoing Allogeneic Hematopoietic Cell Transplantation

Oral Presentation, Abstract 86: Evaluation of Clinical Outcomes and Healthcare Resource Use of Outpatient Allogeneic Stem Cell Transplant in Older Adults with AML/MDS, Using JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning – a Single Center Analysis

Poster, Abstract 211: Initial Results from Stanford Children’s Fanconi Anemia Clinical Trial Using JSP191 Antibody Conditioning and TCRαβ+ T-Cell/CD19+ B-Cell Depleted Grafts

Poster, Abstract 351: Immune Biomarkers Associated with Chronic Gvhd in Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning in Older Adults with MDS/AML Undergoing Allogeneic HCT

Sep 15 · linkedin

I’m happy to share that I’m starting a new position as Vice President, Corporate Development, Portfolio Strategy & Management at Jasper Therapeutics! In addition to Jasper corporate development, I will serve as the program team leader for JSP191. JSP191, now known as briquilimab, is a big part of what originally brought me to Jasper given its potential to transform the field of stem cell therapeutics as a targeted HSC depleting agent. I'm looking forward to working with our team at Jasper to launch our Phase III trial in AML and MDS next year and bring this program to as many patients as we can.   We're #hiring so feel free to reach out to me if you see a role you're interested in or if you'd like to discuss innovation in hematopoietic stem cell therapies!

Related Questions

How did David Ku cultivate his leadership skills in the biotechnology industry?
What inspired David Ku to pursue a career at the intersection of medicine and corporate strategy?
In what ways has David Ku's education at MIT contributed to his work in biopharmaceutical development?
What are the key challenges David Ku faces in his role as VP of Corporate Development at Jasper Therapeutics?
How does David Ku's experience at McKinsey influence his strategic planning at Gilead and Jasper Therapeutics?
David Ku, MD
Add to my network

Location

San Francisco, California, United States